Combining metabolic fingerprinting and footprinting to understand the phenotypic response of HPV16 E6 expressing cervical carcinoma cells exposed to the HIV anti-viral drug lopinavir.
Recently, it has been reported that the anti-viral drug, lopinavir, which is currently used as a human immunodeficiency virus (HIV) protease inhibitor, could also inhibit E6-mediated proteasomal degradation of mutant p53 in E6-transfected C33A cells. In this study, C33A parent control cells and HPV16 E6-transfected cells were exposed to lopinavir at concentrations ranging from 0 to 30 microM. The phenotypic response was assessed by Fourier transform infrared (FT-IR) spectroscopy directly on cells (the metabolic fingerprint) and on the cell growth medium (the metabolic footprint). Multivariate analysis of the data using both principal components analysis (PCA) and canonical variates analysis (PC-CVA) showed trends in scores plots that were related to the concentration of the drug. Inspection of the PC-CVA loadings vector revealed that the effect was not due to the drug alone and that several IR spectral regions including proteins, nucleotides and carbohydrates contributed to the separation in PC-CVA space. Finally, partial least squares regression (PLSR) could be used to predict the concentration of the drug accurately from the metabolic fingerprints and footprints, indicating a dose related phenotypic response. This study shows that the combination of metabolic fingerprinting and footprinting with appropriate chemometric analysis is a valuable approach for studying cellular responses to anti-viral drugs.
Kim
Dong-Hyun
DH
School of Chemistry, Manchester Interdisciplinary Biocentre, The University of Manchester, 131 Princess Street, Manchester, M1 7DN, UK.
Jarvis
Roger M
RM
Xu
Yun
Y
Oliver
Anthony W
AW
Allwood
J William
JW
Hampson
Lynne
L
Hampson
Ian N
IN
Goodacre
Royston
R
D019380:Anti-HIV Agents / Q000494:pharmacology*; D002277:Carcinoma / Q000821:virology*; D045744:Cell Line, Tumor; D005260:Female; D006801:Humans; D061466:Lopinavir; D055432:Metabolomics / Q000379:methods*; D009856:Oncogene Proteins, Viral / Q000378:metabolism*; D010641:Phenotype; D025341:Principal Component Analysis; D011744:Pyrimidinones / Q000494:pharmacology*; D012097:Repressor Proteins / Q000378:metabolism*; D017550:Spectroscopy, Fourier Transform Infrared / Q000379:methods*; D002583:Uterine Cervical Neoplasms / Q000821:virology*
D019380:Anti-HIV Agents; C068651:E6 protein, Human papillomavirus type 16; D009856:Oncogene Proteins, Viral; D011744:Pyrimidinones; D012097:Repressor Proteins; D061466:Lopinavir